Photobiomodulation with the Proactive MR5 Platform in Regenerative Medicine: An Umbrella Study of Mechanisms, Orthobiologic Modulation, and Musculoskeletal Clinical Effects

Table 5: Preclinical and translational evidence for photobiomodulation as a priming or adjuvant modality for orthobiologic substrates (PRP, BMAC-relevant MSCs, ADSCs, exosomes, tenogenic differentiation).

The Proactive MR5 / Multiwave Locked System Platform: Device-Specific Evidence

The MR5 family (ASA Laser, Vicenza, Italy) applies the proprietary MLS® (Multiwave Locked System) technology, in which two distinct emissions are synchronised within a single impulse: an 808 nm continuous-wave diode (typically associated with anti-inflammatory, anti-oedema, and microcirculatory effects at moderate irradiance) and a 905 nm super-pulsed diode (typically associated with analgesic effect and deeper penetration, with peak pulse output in the tens of watts). The dual-emission design is deliberately positioned inside the two WALT-endorsed wavelength windows (780–860 nm and 904 nm), with 808 nm demonstrably the coolest of the commonly used PBM wavelengths per unit irradiance. The MR5 LaserShower and MR5 ACTIV PRO configurations extend this dual-emission over a larger projected area, allowing shorter treatment times per session and access to clinician-facing presets, including Tissue Repair. Institutional literature reports evidence for osteoarthritis (knee highest evidence; shoulder, wrist, hip, ankle, lumbar moderate), rheumatoid arthritis, bursitis, sprain/contusion, tendinopathy, and myalgia/myofascial pain [19].

Peer-reviewed device-specific evidence remains modest but consistently positive. The largest RCT to date is Alayat et al. (2017), a randomised placebo-controlled trial (n = 75) of chronic neck pain in which MLS + exercise reduced VAS by Δ6.68 and NDI by Δ39.84, greater than LLLT (830 nm) + exercise (Δ5.72; Δ37.88) and placebo laser + exercise (Δ4.84; Δ36.68) at 6 weeks. Arefi et al. (2025), a 30-patient randomised double-blind trial in chronic low back pain, reported VAS reduction from 7.66 ± 1.11 to 1.86 ± 0.74 (p = 0.001) with 12 MLS sessions (905 nm, 25/75 W peak, 8 points) versus 7.73 → 5.60 with exercise therapy alone, and normalisation of pin-prick, light-touch, and EMG/NCS in the intervention group. Iacopetti et al. (2015) tested two MLS dose regimens (5 vs 2.5 J/cm²; 10 treatments) in six sheep with collagenase-induced tendinopathy and reported an anti-inflammatory response and return to normal cell number only at the 2.5 J/cm² dose, providing preclinical support for the biphasic Arndt–Schulz principle at MLS parameters [31,32,33].

Table 6: Direct evidence on the Proactive MR5 / MLS platform in musculoskeletal medicine.

Three device-specific gaps are apparent. First, no randomised sham-controlled trial has yet tested MLS-delivered MR5 in knee osteoarthritis, the indication with the strongest generic PBM evidence — a straightforward and high-yield trial opportunity. Second, no published clinical trial has tested the MR5 LaserShower Tissue Repair preset in either of its two possible roles: (a) as an in-vivo adjuvant to intra-articular orthobiologics, or (b) as an ex-vivo priming step for PRP, BMAC, ADSCs, or exosomes before injection. Third, the MR5 combined MLS + LED / UVA multi-wavelength modes are not yet the subject of any indexed randomised trial in orthobiologic medicine.

Discussion

What the umbrella evidence supports

Three conclusions can be defended at the umbrella level. First, PBM in the 600–940 nm window has a coherent, replicated mechanistic basis — mitochondrial CCO activation, NO photodissociation, ROS-mediated redox signalling, and Ca²⁺-dependent opsin/TRP effects — that plausibly explains anti-inflammatory, analgesic, angiogenic, and pro-regenerative outcomes in multiple tissue types. Second, when doses are WALT-compliant and wavelength selection matches tissue depth, PBM produces short- to mid-term pain and disability improvements of clinical magnitude in knee osteoarthritis, lateral elbow tendinopathy, shoulder impingement, temporomandibular disorders, plantar fasciitis, and non-specific low back / neck pain. Third, PBM is safe: no included meta-analysis reported serious adverse events attributable to PBM at recommended doses [1,7,8,11,12,15].

Where uncertainty remains

Several sources of uncertainty are pervasive. Meta-analytic certainty is generally low to very low (GRADE) because primary trials have unclear or high risk of bias, use heterogeneous dosimetry, and rarely report irradiance and fluence in a TIDieR-compliant way. Signal-to-noise degradation is a real risk in meta-analyses that pool trials with 10-fold differences in fluence and 100-fold differences in output power. Achilles tendinopathy (Shriya 2024) and carpal tunnel syndrome (Lauxen 2025) illustrate this ceiling: PBM added to an already effective mechanical intervention or a condition with strong surgical alternatives may not reveal a marginal effect at pooled level. Fracture healing at pooled level is neutral. Publication bias is not systematically assessed in most included SRs. Notably, no included SR reported a formal AMSTAR-2 rating, and few registered a protocol on PROSPERO [10,17,33].

The orthobiologic priming rationale

The strongest translational rationale for combining PBM with orthobiologics rests on four convergent findings: (i) PBM increases mitochondrial ATP and reduces mitochondrial ROS-mediated senescence markers in aged BM-MSCs (Eroglu 2021), (ii) PBM increases proliferation and exosome protein yield in ADSCs with preserved vesicle size ~86 nm (Mirzaei Seresht 2025), (iii) PBM combined with PRP produces greater reductions in intra-articular inflammation than either intervention alone (Gonçalves 2021), and (iv) PBM added to PRP or PRGF significantly increases fibroblast ATP output ex vivo (Abdullah 2025). Together, these suggest that ex-vivo photonic priming of an orthobiologic substrate prior to injection may enhance the substrate's biological readiness — a hypothesis directly testable with the MR5 LaserShower Tissue Repair preset in a controlled bench-to-bedside sequence, as already described in the user's parallel programme.

Practical implications for the Proactive MR5 platform

Based on this synthesis, the following device-explicit recommendations can be drawn for clinicians using the Proactive MR5 platform:

• Knee OA: apply the MR5 dual-emission across the anteromedial and joint-line areas at doses that deliver ≥4 J per point over the 785–860 nm continuous component and ≥1 J per point over the 904 nm super-pulsed component; 5–16 sessions over 2–4 weeks. Where LaserShower is used, log irradiance and fluence explicitly to satisfy TIDieR reporting.
• Lateral elbow tendinopathy: target ≥2 J per tender/trigger point and 2–3 points along the extensor origin at 904/905 nm; expect the largest single-indication effect (WMD −17.2 mm VAS).
• Shoulder impingement / rotator cuff tendinopathy: apply MLS + supervised exercise, following the Alayat 2017 protocol as an operational anchor.
• Chronic neck / low back pain: 12 sessions over 6 weeks at 905 nm super-pulsed with distributed multi-point application; combine with exercise (evidence from Alayat 2017 and Arefi 2025).
• Ex-vivo orthobiologic priming: treat as an experimental protocol requiring bench dosimetry (irradiance and fluence measured through the sterile container, temperature and pH control, platelet count and integrity, growth-factor kinetics) before clinical use — as described in the user's Fotobiomodulação ex-vivo de ortobiológicos programme.
• Do not use MR5 alone as a substitute for surgery or as monotherapy in carpal tunnel syndrome, established rotator cuff tear, or high-grade osteoarthritis where structural surgery is indicated.

Research agenda

A prioritised research agenda for the MR5 platform in regenerative medicine follows directly from the gaps identified.

• Randomised sham-controlled trial of MR5 in symptomatic knee OA (Kellgren–Lawrence 2–3), using WALT-compliant dosing and KOOS-4 as the primary outcome, reported per TIDieR and CONSORT-Laser extensions.
• Factorial 2×2 trial of PRP × PBM in lateral epicondylalgia (PRTEE) and knee OA (KOOS-4), each with concurrent sham arms — isolating PBM effect from PRP effect and from any PBM × PRP interaction.
• Bench dosimetry programme quantifying irradiance and fluence through the actual PRP container walls, verifying platelet integrity, pH, osmolarity, growth-factor kinetics (PDGF, TGF-β, VEGF), and any change in EV/exosome yield or size.
• Ex-vivo photonic priming of BMAC, ADSCs, and MSC-derived EVs at defined MR5 doses, with functional assays on target cells (chondrocytes, tenocytes, myoblasts).
• Head-to-head evaluation of MR5 (MLS dual-emission) vs matched single-wavelength LLLT devices for the same indication, controlling for delivered energy — the only design that can support device-specific labelling claims.
• Formal AMSTAR-2 appraisal and PROSPERO registration for future PBM systematic reviews, per PRIOR guidance.

Limitations

Three limitations of the present umbrella study should be recognised. First, no re-pooling of individual-patient data was performed; effect sizes reported are those extracted from the primary source reviews, which themselves carry pooling assumptions. Second, formal AMSTAR-2 numerical scoring was not repeated for each included systematic review; instead, qualitative appraisal of the seven AMSTAR-2 critical domains was applied. Third, our dedicated MR5 / MLS evidence base is small (three peer-reviewed clinical/preclinical studies plus institutional literature), reflecting an authentic evidence gap that is itself one of our findings. Publication bias in PBM literature is plausible given the volume of positive small trials and warrants funnel-plot analysis in any future device-specific meta-analysis.

Conclusions

Photobiomodulation in the 600–940 nm window has a coherent mitochondrial and redox-signalling mechanism, a WALT-endorsed dosimetric framework, and reproducible short- to mid-term clinical benefit in several musculoskeletal indications — most robustly in knee osteoarthritis, lateral epicondylitis, shoulder impingement, temporomandibular disorders, and chronic neck / low back pain — when wavelength-appropriate and dose-transparent protocols are used. The Proactive MR5 platform, with its synchronised 808 nm continuous and 905 nm super-pulsed MLS® emissions, is spectrally well-positioned inside this evidence window. Its dual-emission architecture is biologically rational for combined use with orthobiologics, and translational preclinical evidence supports ex-vivo photonic priming of PRP, ADSCs, and exosomes. However, device-specific randomised sham-controlled trials of MR5 in knee OA and orthobiologic priming remain the essential next step before adjuvant use can be considered evidence-based. A properly designed factorial trial and a bench-dosimetry programme are, at this moment, the two most valuable investments the field can make.

Declarations

Ethics approval and consent to participate: Not applicable (overview of published evidence).

Availability of data and materials: Full extraction tables and search logs are available from the corresponding author upon reasonable request.

Competing interests: The authors declare no financial relationship with ASA Laser or any manufacturer of photobiomodulation equipment. Any future updates will disclose any change in this status.

Funding: No external funding was received for this work.

Author contributions: All authors: conception, evidence retrieval, extraction, synthesis, drafting, and final approval.

Acknowledgements: The author acknowledges the WALT and ASAcampus initiatives for maintaining publicly accessible dose recommendations and mechanistic photobiology literature.

References

1. Stausholm MB, Naterstad IF, Joensen J, Lopes-Martins RÁB, Sæbø H, Lund H, Fersum KV, Bjordal JM. Efficacy of low-level laser therapy on pain and disability in knee osteoarthritis: systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2019;9(10):e031142.
2. Oliveira S, Andrade R, Valente C, Espregueira-Mendes J, Silva FS, Hinckel BB, Carvalho Ó, Leal A. Effectiveness of photobiomodulation in reducing pain and disability in patients with knee osteoarthritis: a systematic review with meta-analysis. Phys Ther. 2024;104(8):pzae073. 
3. Hennessy SN, Corcoran GD. Low-level laser therapy in osteoarthritic pain: a narrative review with an approach to integrated clinical use. Osteoarthr Cartil Open. 2025;7(4):100685. 
4. Xia P, Fan T, Huang Y, Zheng H, Ma R, Zhou W, et al. Photobiomodulation for the treatment of knee osteoarthritis: therapeutic effects and molecular mechanism. Front Cell Dev Biol. 2026;14:1744761. 
5. Chen H, Gao F, Luo Y, Wang R, Niken AD, Xu Z, Ding Y, Guo Y. From concept to practice: intra-articular photobiomodulation for knee osteoarthritis. Front Immunol. 2026;17:1793440. 
6. Chang WD, Wu JH, Yang WJ, Jiang JA. Therapeutic effects of low-level laser on lateral epicondylitis from differential interventions of Chinese-Western medicine: systematic review. Photomed Laser Surg. 2010;28(3):327–336. 
7. Mamais I, Papadopoulos K, Lamnisos D, Stasinopoulos D. Effectiveness of low-level laser therapy (LLLT) in the treatment of lateral elbow tendinopathy (LET): an umbrella review. Laser Ther. 2018;27(3):174–186. 
8. Quagliotto GL, Manchope MP, Hilario R, Zubeldia V, Stacheslki RA, de Carvalho AR, Buzanello MR, Bertolini GRF. Photobiomodulation associated with physical exercise in shoulder impingement syndrome: systematic review with meta-analysis. Photochem Photobiol. 2026;102(1):220–236. 
9. Wang W, Jiang W, Tang C, Zhang X, Xiang J. Clinical efficacy of low-level laser therapy in plantar fasciitis: a systematic review and meta-analysis. Medicine (Baltimore). 2019;98(3):e14088.
10. Lauxen AC, Machado DR, Pereira DS, de Medeiros LB, Bertoncello D, Buzanello MR, Bertolini GRF. Photobiomodulation in carpal tunnel syndrome with pain, strength and function outcomes. Lasers Med Sci. 2025;40(1):12. 
11. Sobral APT, Sobral SS, Campos TM, Horliana ACRT, Fernandes KPS, Bussadori SK, Motta LJ. Photobiomodulation and myofascial temporomandibular disorder: systematic review and meta-analysis with cost-effectiveness analysis. J Clin Exp Dent. 2021;13(7):e724–e732. 
12. Hanna R, Dalvi S, Bensadoun RJ, Benedicenti S. Role of photobiomodulation therapy in modulating oxidative stress in temporomandibular disorders: systematic review and meta-analysis of human randomised controlled trials. Antioxidants. 2021;10(7):1028. 
13. Rosso MPO, Buchaim DV, Kawano N, Furlanette G, Pomini KT, Buchaim RL. Photobiomodulation therapy (PBMT) in peripheral nerve regeneration: systematic review. Bioengineering (Basel). 2018;5(2):44. 
14. Korada HY, Arora E, Maiya GA, Rao S, Hande M, Shetty S, Gundmi S, Anche P, Amravadi S. Effectiveness of photobiomodulation therapy on neuropathic pain in patients with diabetic peripheral neuropathy: systematic review. Curr Diabetes Rev. 2023;19(9):e290422204244. 
15. De Oliveira MF, Johnson DS, Demchak T, Tomazoni SS, Leal-Junior EC. Low-intensity LASER and LED (photobiomodulation therapy) for pain control of the most common musculoskeletal conditions. Eur J Phys Rehabil Med. 2022;58(2):282–289. 
16. Aguirra P, do Nascimento AP, Casonatto J, Ribeiro AS, de Oliveira RG, Pacagnelli FL, Aguiar AF. Systematic review and meta-analysis of the acute effects of photobiomodulation therapy on maximum repetitions in resistance exercise in young adults. Lasers Med Sci. 2025;40:184. 
17. Hazrati P, Azadi A, Fekrazad S, Wang HL, Fekrazad R. Effect of photobiomodulation therapy on fracture healing: systematic review and meta-analysis of animal studies. Lasers Med Sci. 2025;40(1):121. 
18. Miranda MB, Alves RF, Rocha RB, Cardoso VS. Effects and parameterization of low-level laser therapy in diabetic ulcers: an umbrella review of systematic reviews and meta-umbrella. Lasers Med Sci. 2025;40(1):109. 
19. World Association for Photobiomodulation Therapy. Dose table 904 nm for low-level laser therapy — WALT 2010. Revised April 2010. 
20. Hang NLT, Aviña AE, Chang CJ, Yang TS. Photobiomodulation in promoting cartilage regeneration. Int J Mol Sci. 2025;26(12):5580. 
21. Tim CR, Martignago CCS, Assis L, Neves LM, Andrade AL, Silva NC, Parizotto N, Pinto KZ, Rennó AC. Effects of photobiomodulation therapy in chondrocyte response by in vitro experiments and experimental osteoarthritis model in rats. Lasers Med Sci. 2022;37(3):1677–1686.
22. Liu H, Cheema U, Player DJ. Photobiomodulation therapy (PBMT) in skeletal muscle regeneration: comprehensive review of mechanisms, clinical applications, and future directions. Photodiagn Photodyn Ther. 2025;53:104634. 
23. Gonçalves AB, Bovo JL, Gomes BS, Pigoso AA, Felonato M, Esquisatto MAM, Lopes Filho GJ, Bomfim FRCD. Photobiomodulation (λ=808 nm) and platelet-rich plasma (PRP) for the treatment of acute rheumatoid arthritis in Wistar rats. J Lasers Med Sci. 2021;12:e60.
24. Barbosa D, de Souza RA, de Carvalho WRG, Xavier M, de Carvalho PK, Cunha TCR, Arisawa EÂL, Silveira L Jr, Villaverde AB. Low-level laser therapy combined with platelet-rich plasma on the healing of Achilles tendon. Lasers Med Sci. 2013;28(6):1489–1494. 
25. Prodromos CC, Finkle S, Dawes A, Dizon A. Intra-articular laser treatment plus platelet-rich plasma (PRP) significantly reduces pain in many patients who had failed prior PRP treatment. Medicines (Basel). 2019;6(3):75. 
26. Abdullah SH, Mokhtari-Dizaji M, Hormozi-Moghaddam Z, Bakhshandeh M, Nilforoshzadeh MA. Laser photobiomodulation of human dermal fibroblasts combined with plasma rich in growth factors and platelet-rich plasma: a comparative in vitro analysis. Photodermatol Photoimmunol Photomed. 2025;41(6):e70063. 
27. Ahrabi B, Rezaei Tavirani M, Khoramgah MS, Noroozian M, Darabi S, Khoshsirat S, Abbaszadeh HA. Effect of photobiomodulation therapy on the differentiation, proliferation, and migration of mesenchymal stem cell: a review. J Lasers Med Sci. 2019;10(Suppl 1):S96–S103. 
28. Pinto H, Goñi Oliver P, Sánchez-Vizcaíno Mengual E. Effect of photobiomodulation on human mesenchymal cells: literature review. Aesthetic Plast Surg. 2021;45(4):1826–1842. 
29. Rastogi M, Sahu K, Majumder SK. Light-assisted modulation of stem cell function and secretome production: systematic review on current status and new avenues for regenerative medicine. Lasers Med Sci. 2025;40(1):83. 
30. Eroglu B, Genova E, Zhang Q, Su Y, Shi X, Isales C, Eroglu A. Photobiomodulation has rejuvenating effects on aged bone marrow mesenchymal stem cells. Sci Rep. 2021;11:13067. 
31. Mirzaei Seresht P, Amini A, Pourmasoumi P, Hajihosseintehrani M, Ahmadi H, Fallah B, Zare F, Bayat S, Chien S, Albright R, Bayat M. In vitro photobiomodulation enhances human adipose-derived stem cell viability and exosome quality: novel approach for regenerative medicine. Lasers Med Sci. 2025;40(1):308. 
32. Roets B, Abrahamse H, Crous A. Photobiomodulation-driven tenogenic differentiation of MSCs in hydrogel culture. Int J Mol Sci. 2025;26(24):11965. 
33. Alayat MSM, Elsoudany AM, Ali MEA. Efficacy of Multiwave Locked System laser on pain and function in patients with chronic neck pain: randomised placebo-controlled trial. Photomed Laser Surg. 2017;35(8):450–455. 
34. Arefi S, Saidian SR, Mokhtari M, Eliaspour D. MLS laser reduces pain in patients with chronic low back pain: randomised double-blind study. Anesth Pain Med. 2025;15(1):e158778. 
35. Iacopetti I, Perazzi A, Maniero V, Martinello T, Patruno M, Glazar M, Busetto R. Effect of MLS® laser therapy with different dose regimes for treatment of experimentally induced tendinopathy in sheep: pilot study. Photomed Laser Surg. 2015;33(3):154–163.
36. Shriya S, Arya RK, Kushwaha S, Chahar S, Manikandan P, Mehra P. Effectiveness of low-level laser therapy combined with eccentric exercise in treating midportion Achilles tendinopathy: a randomised controlled trial. Cureus. 2024;16(6):e62919. 
37. Hamblin MR. Mechanisms and mitochondrial redox signaling in photobiomodulation. Photochem Photobiol. 2018;94(2):199–212. 
38. Dompe C, Moncrieff L, Matys J, Grzech-Leśniak K, Kocherova I, Bryja A, et al. Photobiomodulation — underlying mechanism and clinical applications. J Clin Med. 2020;9(6):1724. 
39. de Freitas LF, Hamblin MR. Proposed mechanisms of photobiomodulation or low-level light therapy. IEEE J Sel Top Quantum Electron. 2016;22(3):7000417. 
40. Zein R, Selting W, Hamblin MR. Review of light parameters and photobiomodulation efficacy: dive into complexity. J Biomed Opt. 2018;23(12):120901. 
41. Cronshaw M, Parker S, Grootveld M, Lynch E. Photothermal effects of high-energy photobiomodulation therapies: in vitro investigation. Biomedicines. 2023;11(6):1634. 
42. Nie F, Hao S, Ji Y, Zhang Y, Sun H, Will M, Han W, Ding Y. Biphasic dose response in the anti-inflammation experiment of PBM. Lasers Med Sci. 2023;38(1):66.